Food and Drug Administration Safety Act of 2007
Latest action · Feb 2, 2007 Referred to the Subcommittee on Health.
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedJan 31, 2007
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Food and Drug Administration Safety Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act to establish the Center for Postmarket Evaluation and Research for Drugs and Biologics within the Food and Drug Administration (FDA).
Requires the Director of the Center to conduct activities to ensure the safety and effectiveness of FDA-approved drugs and licensed biological products, including by: (1) conducting postmarket risk assessment and surveillance of such drugs and products; (2) determining whether a postmarket study is required; (3) contracting, or requiring the sponsor of such a drug or product to contract, with the holders of domestic and international patient databases to conduct epidemiologic and other observational studies; (4) determining whether a drug or product may present an unreasonable risk to the health of patients or the general public; (5) taking corrective action if such an unreasonable risk may exist; and (6) making information about the safety and effectiveness of such drugs and biological products available to the public and health care providers in a timely manner.
Requires the Drug Safety and Risk Management Advisory Committee to make recommendations to the Director on postmarket studies, drugs and biological products that may present an unreasonable risk, and appropriate corrective actions.
Allows the Secretary of Health and Human Services to assess civil penalties for violations of this Act.
Allows the Director to withdraw or suspend approval of a drug or license for a biological product using expedited procedures under certain circumstances.
Transfers to the Center the functions and duties of the Office of Surveillance and Epidemiology.
Cosponsors 5
Members who signed on, in the order they did. Signatures ran from Jan 31, 2007 to Jul 25, 2007; 1 is an original cosponsor, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| R-MN | Jim Ramstad | Original | Jan 31, 2007 |
| D-CA | George Miller | Jun 12, 2007 | |
| D-MA | James P. McGovern | Jun 12, 2007 | |
| D-MO | Wm. Lacy Clay | Jun 12, 2007 | |
| D-IL | Danny K. Davis | Jul 25, 2007 |
Committees 1
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Jan 31, 2007 |
| Health Subcommittee | Referred Feb 2, 2007 |
Actions 3
Everything that happened, newest first.
- Feb 2, 2007Referred to the Subcommittee on Health.
- Jan 31, 2007Introduced in House
- Jan 31, 2007Referred to the House Committee on Energy and Commerce.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 468 | Food and Drug Administration Safety Act of 2007 | Identical bill | Jan 31, 2007 |
Titles 2
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend the Federal Food, Drug, and Cosmetic Act with respect to drug safety, and for other purposes.
- Short Titles as Introduced
- Food and Drug Administration Safety Act of 2007
Subjects
Assigned by the Library of Congress. Policy area: Health.
- Administrative remedies
- Advertising
- Biomedical engineering
- Clinical trials
- Commerce
- Congress
- Congressional reporting requirements
- Consumer education
- Cost effectiveness
- Data banks
- Department of Health and Human Services
- Drug adulteration
- Drug approvals
- Drug industry
- Epidemiology
- Executive reorganization
- Federal advisory bodies
- Finance and Financial Sector
- Fines (Penalties)
- Food and Drug Administration (FDA)
- Government Operations and Politics
- Government paperwork
- Government publicity
- Health
- Health information systems
- Law
- Licenses
- Medical supplies
- Pharmaceutical research
- Product safety
- Risk
- Sales promotion
- Science, Technology, Communications
Text 1
Each version as it was printed, newest first.
- Jan 31, 2007Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.